drugset / Trial / NCT05054725
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
Timeline
- Start
- 2021-12-30
- Primary completion
- 2024-07-03
- Completion
- 2024-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sotorasib | Small molecule | — | Oral |
| Subject | Vociprotafib | Small molecule | — | Oral |